Colossal Biosciences in Talks for $20–30 Billion Valuation

Axios reports that Colossal Biosciences, the Dallas-based de-extinction company, is in talks to raise new capital at a $20–30 billion valuation. That would double or triple the $10.3 billion figure from its September 2025 round. No lead investor or check size has been disclosed. The five-year-old company has raised $555 million to date and recently began generating revenue.